menu

Sniffing Out the Problem: A Dive into Management for Chronic Rhinosinusitis with Nasal Polyps

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Sniffing Out the Problem: A Dive into Management for Chronic Rhinosinusitis with Nasal Polyps

close
Sniffing Out the Problem: A Dive into Management for Chronic Rhinosinusitis with Nasal Polyps
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Please note:This activity is no longer available for continuing education credit.

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.

  • Faculty Credentials

    Joseph K. Han, MD
    Professor
    Chief,
    Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
    Chief, Division of Allergy
    Eastern Virginia Medical School
    Norfolk, VA

  • Target Audience

    The target audience for this activity is US-based allergy-immunology, ENT, and pulmonology clinicians (physicians, NPs, and PAs) who manage patients with chronic rhinosinusitis with nasal polyps (and/or comorbid asthma).

  • Learning Objectives

    After engaging in this educational initiative, learners will be able to:

    • Accurately diagnose patients with type 2 inflammation-driven nasal polyps (chronic rhinosinusitis with nasal polyps [CRSwNP]) who may be eligible for treatment with biologic therapy
    • Describe the underlying pathophysiology of rhinosinusitis-associated nasal polyps and how this may be used to guide selection of novel biologic therapy
    • Evaluate emerging agents for CRSwNP based on their efficacy and safety data
  • Accreditation Statement

    CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Physicians
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

  • Provider(s)/Educational Partner(s)

    This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with AKH.

  • Commercial Support

    This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclosure of Conflicts of Interest

    It is the policy of RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review.

  • Disclosure Declarations

    Joseph K. Han, MD has affiliations with Astra Zeneca, Genentech, GlaxoSmith Kline, Regeneron, Roche, Sanofi Genzyme (Consultant)

    AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

    Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner: has disclosed no financial relationships.
    Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no financial relationships.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • How to Receive Your Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately.

    Users must:
    -Read the learning objectives and faculty disclosures.
    -Participate in the activity.
    -Complete the activity evaluation.

    Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

    There is no fee to participate.

  • Publication Dates

    Release Date: 12/26/2019

    End Date: This activity is no longer available for continuing education credit. 

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Please note:This activity is no longer available for continuing education credit.

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.

  • Faculty Credentials

    Joseph K. Han, MD
    Professor
    Chief,
    Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
    Chief, Division of Allergy
    Eastern Virginia Medical School
    Norfolk, VA

  • Target Audience

    The target audience for this activity is US-based allergy-immunology, ENT, and pulmonology clinicians (physicians, NPs, and PAs) who manage patients with chronic rhinosinusitis with nasal polyps (and/or comorbid asthma).

  • Learning Objectives

    After engaging in this educational initiative, learners will be able to:

    • Accurately diagnose patients with type 2 inflammation-driven nasal polyps (chronic rhinosinusitis with nasal polyps [CRSwNP]) who may be eligible for treatment with biologic therapy
    • Describe the underlying pathophysiology of rhinosinusitis-associated nasal polyps and how this may be used to guide selection of novel biologic therapy
    • Evaluate emerging agents for CRSwNP based on their efficacy and safety data
  • Accreditation Statement

    CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Physicians
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

  • Provider(s)/Educational Partner(s)

    This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with AKH.

  • Commercial Support

    This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclosure of Conflicts of Interest

    It is the policy of RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review.

  • Disclosure Declarations

    Joseph K. Han, MD has affiliations with Astra Zeneca, Genentech, GlaxoSmith Kline, Regeneron, Roche, Sanofi Genzyme (Consultant)

    AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

    Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner: has disclosed no financial relationships.
    Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no financial relationships.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • How to Receive Your Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately.

    Users must:
    -Read the learning objectives and faculty disclosures.
    -Participate in the activity.
    -Complete the activity evaluation.

    Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

    There is no fee to participate.

  • Publication Dates

    Release Date: 12/26/2019

    End Date: This activity is no longer available for continuing education credit. 

Facebook Comments

Programs 5/9/21